GLUT1 Protein (Glucose Transporter 1)
Overview
GLUT1 (Glucose Transporter 1), encoded by the [SLC2A1](/genes/slc2a1) gene, is the primary facilitative glucose transporter at the [blood-brain barrier](/mechanisms/blood-brain-barrier) (BBB). As the brain consumes ~20% of total body glucose despite comprising only ~2% of body weight, GLUT1 is essential for maintaining cerebral glucose supply. GLUT1 deficiency syndrome causes epileptic encephalopathy, and reduced GLUT1 expression at the [BBB](/entities/blood-brain-barrier) is an early and consistent feature of [Alzheimer's disease](/diseases/alzheimers-disease), preceding neuronal loss by years.
<div class="infobox infobox-protein">
| Property | Value |
|---|---|
| Full Name | Glucose Transporter Type 1 (Solute Carrier Family 2 Member 1) |
| Gene | [SLC2A1](/genes/slc2a1) |
| UniProt | [P11166](https://www.uniprot.org/uniprot/P11166) |
| Molecular Weight | 54 kDa (glycosylated) |
| Structure | 12 transmembrane domains, Major Facilitator Superfamily |
| Subcellular Location | Plasma membrane (apical and basolateral in endothelial cells) |
| Expression | BBB endothelium, erythrocytes, astrocytic endfeet, oligodendrocytes |
| Associated Diseases | GLUT1 deficiency syndrome, [Alzheimer's disease](/diseases/alzheimers-disease), epilepsy |
| PDB | [4PYP](https://www.rcsb.org/structure/4PYP) |
</div>
Structure and Transport Mechanism
...GLUT1 Protein (Glucose Transporter 1)
Overview
GLUT1 (Glucose Transporter 1), encoded by the [SLC2A1](/genes/slc2a1) gene, is the primary facilitative glucose transporter at the [blood-brain barrier](/mechanisms/blood-brain-barrier) (BBB). As the brain consumes ~20% of total body glucose despite comprising only ~2% of body weight, GLUT1 is essential for maintaining cerebral glucose supply. GLUT1 deficiency syndrome causes epileptic encephalopathy, and reduced GLUT1 expression at the [BBB](/entities/blood-brain-barrier) is an early and consistent feature of [Alzheimer's disease](/diseases/alzheimers-disease), preceding neuronal loss by years.
<div class="infobox infobox-protein">
| Property | Value |
|---|---|
| Full Name | Glucose Transporter Type 1 (Solute Carrier Family 2 Member 1) |
| Gene | [SLC2A1](/genes/slc2a1) |
| UniProt | [P11166](https://www.uniprot.org/uniprot/P11166) |
| Molecular Weight | 54 kDa (glycosylated) |
| Structure | 12 transmembrane domains, Major Facilitator Superfamily |
| Subcellular Location | Plasma membrane (apical and basolateral in endothelial cells) |
| Expression | BBB endothelium, erythrocytes, astrocytic endfeet, oligodendrocytes |
| Associated Diseases | GLUT1 deficiency syndrome, [Alzheimer's disease](/diseases/alzheimers-disease), epilepsy |
| PDB | [4PYP](https://www.rcsb.org/structure/4PYP) |
</div>
Structure and Transport Mechanism
GLUT1 belongs to the Major Facilitator Superfamily (MFS) of membrane transporters. The crystal structure (solved in 2014 at 3.2 Å resolution) reveals 12 transmembrane α-helices arranged in two six-helix bundles (N-domain and C-domain) that form a central hydrophilic cavity[@deng2014]. Transport occurs via an alternating access mechanism:
Outward-open conformation — glucose binds to the extracellular vestibule
Occluded state — the transporter closes around the substrate
Inward-open conformation — glucose is released into the cytoplasm
Reset — the empty transporter returns to the outward-open stateKey structural features include:
- Substrate selectivity filter — residues Gln282, Gln283, Asn288, and Trp388 coordinate glucose binding via hydrogen bonds
- ICH domain — intracellular helical domain acts as a latch that stabilizes the outward-open conformation
- N-glycosylation — Asn45 is heavily glycosylated, which is required for proper membrane targeting and protein stability
GLUT1 has a Km for glucose of ~1-2 mM, well below normal blood glucose (~5 mM), ensuring near-saturation under physiological conditions. However, this means GLUT1 cannot compensate for reduced transporter density by increasing per-molecule transport rate[@mergenthaler2013].
GLUT1 at the Blood-Brain Barrier
At the BBB, GLUT1 is expressed on both the luminal (blood-facing) and abluminal (brain-facing) membranes of brain endothelial cells, mediating the transcellular transport of glucose from blood to brain interstitium. GLUT1 is also expressed on [astrocytic](/cell-types/astrocytes) endfeet that ensheath brain capillaries, facilitating glucose uptake into [astrocytes](/entities/astrocytes) for lactate shuttle delivery to [neurons](/entities/neurons)[@simpson2007].
BBB GLUT1 exists as a 55 kDa glycoprotein (distinct from the 45 kDa erythrocyte isoform due to differential glycosylation). Its expression is regulated by:
- Hypoxia — HIF-1α transcriptionally upregulates GLUT1 via hypoxia-response elements in the SLC2A1 promoter
- VEGF signaling — vascular endothelial growth factor increases GLUT1 transcription and membrane trafficking
- Insulin signaling — unlike GLUT4, GLUT1 is not insulin-responsive; BBB glucose transport is insulin-independent
- Amyloid-β — Aβ downregulates GLUT1 expression in brain endothelial cells via [NF-κB](/entities/nf-kb)-mediated transcriptional repression[@winkler2015]
Role in Alzheimer's Disease
GLUT1 reduction at the BBB is one of the earliest detectable abnormalities in [Alzheimer's disease](/diseases/alzheimers-disease) and in individuals at genetic risk (e.g., [APOE](/genes/apoe) ε4 carriers)[@mosconi2008]:
The hallmark glucose hypometabolism detected by ¹⁸Ffluorodeoxyglucose PET (FDG-PET) in AD — particularly in the posterior cingulate [cortex](/brain-regions/cortex), precuneus, and temporoparietal regions — is driven in part by reduced GLUT1-mediated glucose delivery across the BBB, not solely by reduced neuronal glucose utilization[@landau2011].
Mechanisms of GLUT1 Reduction in AD
Aβ-mediated downregulation — [Aβ42](/proteins/amyloid-beta) oligomers activate NF-κB in endothelial cells, suppressing SLC2A1 transcription. Chronic Aβ exposure reduces GLUT1 protein by 40-50% in vitro[@winkler2015]
Pericyte loss — [pericytes](/cell-types/pericytes) maintain GLUT1 expression in endothelial cells via paracrine signaling; pericyte degeneration in AD reduces GLUT1 levels
Oxidative stress — chronic oxidative damage to endothelial membranes accelerates GLUT1 turnover
Vascular inflammation — [TNF-α](/proteins/tnf-alpha-protein) and [IL-1β](/proteins/il1b-protein) from activated [microglia](/cell-types/microglia) reduce GLUT1 transcriptionConsequences of GLUT1 Deficiency
In mouse models, endothelial-specific GLUT1 haploinsufficiency (Slc2a1+/-) accelerates AD pathology by:
- Reducing cerebral glucose metabolism and increasing compensatory ketone utilization
- Accelerating Aβ accumulation (impaired clearance due to BBB dysfunction)
- Promoting [tau](/proteins/tau) hyperphosphorylation via energy-sensing kinase activation ([GSK-3β](/entities/gsk3-beta), AMPK)
- Increasing BBB permeability and neurovascular uncoupling[@an2018]
Conversely, GLUT1 overexpression in 5xFAD mice reduces Aβ plaque burden, restores cerebral glucose uptake, and improves cognitive performance, establishing a causal role for GLUT1 in AD pathogenesis[@an2018].
Role in Other Neurodegenerative Diseases
GLUT1 Deficiency Syndrome
Heterozygous loss-of-function mutations in SLC2A1 cause GLUT1 deficiency syndrome (De Vivo disease), characterized by infantile seizures, microcephaly, developmental delay, and movement disorders. CSF glucose is characteristically low (CSF:blood glucose ratio <0.4). The ketogenic diet is the standard treatment, bypassing the need for glucose transport[@pascual2004].
Parkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease), FDG-PET shows relative glucose hypermetabolism in the putamen and cerebellum (compensatory) but hypometabolism in the frontal cortex. GLUT1 expression is reduced in cortical microvessels of PD patients with cognitive impairment[@teune2010].
Huntington's Disease
[Huntington's disease](/diseases/huntington-disease) features early striatal glucose hypometabolism. Mutant [huntingtin](/proteins/huntingtin-protein) directly impairs GLUT1-mediated glucose uptake in striatal neurons, contributing to energy failure and vulnerability to excitotoxicity[@gamberino2000].
Therapeutic Implications
GLUT1 is an emerging therapeutic target in neurodegeneration:
- Gene therapy — AAV-mediated SLC2A1 overexpression in brain endothelium restores glucose transport in mouse models
- Pharmacological upregulation — triheptanoin (anaplerotic substrate), ketogenic diet, and PPAR agonists can partially compensate for reduced GLUT1
- Biomarker potential — CSF glucose/lactate ratio and FDG-PET patterns reflecting GLUT1 insufficiency may serve as early AD biomarkers
- GLUT1 stabilizers — small molecules that stabilize GLUT1 membrane expression are under preclinical investigation[@an2018]
See Also
- [SLC2A1 Gene](/genes/slc2a1)
- [Blood-Brain Barrier in Neurodegeneration](/mechanisms/blood-brain-barrier-neurodegeneration)
- [Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction-ad)
- [Cerebral Glucose Metabolism](/mechanisms/glucose-metabolism-neurodegeneration)
- [Astrocytes](/cell-types/astrocytes)
External Links
- [GLUT1 — UniProt P11166](https://www.uniprot.org/uniprot/P11166)
- [SLC2A1 — NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/6513)
- [GLUT1 Deficiency — OMIM](https://www.omim.org/entry/606777)
- [GLUT1 Structure — PDB 4PYP](https://www.rcsb.org/structure/4PYP)
References
[Mergenthaler P et al., Sugar for the brain: the role of glucose in physiological and pathological brain function (2013) (2013)](https://doi.org/10.1016/j.tins.2013.07.001)
[Winkler EA et al., GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration (2015) (2015)](https://doi.org/10.1038/nn.3966)
[Deng D et al., Crystal structure of the human glucose transporter GLUT1 (2014) (2014)](https://doi.org/10.1038/nature13616)
[Simpson IA et al., Supply and demand in cerebral energy metabolism: the role of nutrient transporters (2007) (2007)](https://doi.org/10.1038/sj.jcbfm.9600521)
[Mosconi L et al., Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease (2008) (2008)](https://doi.org/10.1111/j.1749-6632.2008.03768.x)
[Landau SM et al., Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI (2011) (2011)](https://doi.org/10.1016/j.neurobiolaging.2009.07.002)
[An Y et al., Evidence for brain glucose dysregulation in Alzheimer's disease (2018) (2018)](https://doi.org/10.1186/s13195-018-0370-8)
[Pascual JM et al., GLUT1 deficiency and other glucose transporter diseases (2004) (2004)](https://doi.org/10.1111/j.0013-9580.2004.13504.x)
[Teune LK et al., Typical cerebral metabolic patterns in neurodegenerative brain diseases (2010) (2010)](https://doi.org/10.1002/mds.23291)
[Unknown, Gamberino WC & Bhatt MS, Glucose transporter isoform expression and regulation in the developing and adult brain (2000) (2000)](https://doi.org/10.1046/j.1471-4159.2000.0740240.x)